93M1 Fundamental Analysis - MPH HEALTH CARE AG KONV

Fundamental Rating

Overall 93M1 gets a fundamental rating of 3 out of 10. We evaluated 93M1 against 50 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of 93M1 have multiple concerns. 93M1 does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year 93M1 was profitable.

In the past year 93M1 had a positive cash flow from operations.

In multiple years 93M1 reported negative net income over the last 5 years.

In multiple years 93M1 reported negative operating cash flow during the last 5 years.

1.2 Ratios

93M1's Return On Assets of 11.01% is fine compared to the rest of the industry. 93M1 outperforms 72.00% of its industry peers.

With a Return On Equity value of 11.53%, 93M1 perfoms like the industry average, outperforming 52.00% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	11.01%
ROE	11.53%
ROIC	N/A

ROA(3y)11.46%

ROA(5y)-0.71%

ROE(3y)12.15%

ROE(5y)-0.63%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin of 93M1 (105749.17%) is better than 100.00% of its industry peers.

93M1's Profit Margin has improved in the last couple of years.

The Operating Margin and Gross Margin are not available for 93M1 so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	105749.17%
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5Y32.91%

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

93M1 does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for 93M1 remains at a similar level compared to 1 year ago.

Compared to 5 years ago, 93M1 has about the same amount of shares outstanding.

The debt/assets ratio for 93M1 has been reduced compared to a year ago.

2.2 Solvency

93M1 has an Altman-Z score of 4.71. This indicates that 93M1 is financially healthy and has little risk of bankruptcy at the moment.

The Altman-Z score of 93M1 (4.71) is better than 72.00% of its industry peers.

The Debt to FCF ratio of 93M1 is 13.58, which is on the high side as it means it would take 93M1, 13.58 years of fcf income to pay off all of its debts.

With a Debt to FCF ratio value of 13.58, 93M1 is not doing good in the industry: 62.00% of the companies in the same industry are doing better.

A Debt/Equity ratio of 0.02 indicates that 93M1 is not too dependend on debt financing.

With an excellent Debt to Equity ratio value of 0.02, 93M1 belongs to the best of the industry, outperforming 88.00% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.02
Debt/FCF	13.58
Altman-Z	4.71

ROIC/WACCN/A

WACC6.99%

2.3 Liquidity

A Current Ratio of 0.52 indicates that 93M1 may have some problems paying its short term obligations.

Looking at the Current ratio, with a value of 0.52, 93M1 is doing worse than 88.00% of the companies in the same industry.

93M1 has a Quick Ratio of 0.52. This is a bad value and indicates that 93M1 is not financially healthy enough and could expect problems in meeting its short term obligations.

Looking at the Quick ratio, with a value of 0.52, 93M1 is doing worse than 88.00% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	0.52
Quick Ratio	0.52

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 8.45% over the past year.

The Earnings Per Share has been growing by 23.67% on average over the past years. This is a very strong growth

Looking at the last year, 93M1 shows a quite strong growth in Revenue. The Revenue has grown by 17.44% in the last year.

93M1 shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -6.95% yearly.

EPS 1Y (TTM)8.45%

EPS 3YN/A

EPS 5Y23.67%

EPS Q2Q%-194.51%

Revenue 1Y (TTM)17.44%

Revenue growth 3Y-4.71%

Revenue growth 5Y-6.95%

Sales Q2Q%39.52%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

93M1 is valuated cheaply with a Price/Earnings ratio of 2.35.

Compared to the rest of the industry, the Price/Earnings ratio of 93M1 indicates a rather cheap valuation: 93M1 is cheaper than 100.00% of the companies listed in the same industry.

93M1's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.06.

		Industry Rank	Sector Rank
PE	2.35
Fwd PE	N/A

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, 93M1 is valued a bit more expensive than 62.00% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	96.63
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)0.1

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 6.96%, 93M1 is a good candidate for dividend investing.

93M1's Dividend Yield is rather good when compared to the industry average which is at 3.06. 93M1 pays more dividend than 96.00% of the companies in the same industry.

Compared to an average S&P500 Dividend Yield of 2.41, 93M1 pays a better dividend.

		Industry Rank	Sector Rank
Dividend Yield	6.96%

5.2 History

Dividend Growth(5Y)N/A

Div Incr Years0

Div Non Decr Years0

5.3 Sustainability

DP0%

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

MPH HEALTH CARE AG KONV

FRA:93M1 (9/5/2025, 7:00:00 PM)

17.55

+0.3 (+1.74%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)06-09 2025-06-09

Earnings (Next)N/A N/A

Inst Owners0.87%

Inst Owner ChangeN/A

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap75.11M

Analysts85.71

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	6.96%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DP0%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	2.35
Fwd PE	N/A
P/S	2479.01
P/FCF	96.63
P/OCF	96.12
P/B	0.27
P/tB	0.27
EV/EBITDA	N/A

EPS(TTM)7.48

EY42.62%

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)0.18

FCFY1.03%

OCF(TTM)0.18

OCFY1.04%

SpS0.01

BVpS64.92

TBVpS64.92

PEG (NY)N/A

PEG (5Y)0.1

Profitability

		Industry Rank	Sector Rank
ROA	11.01%
ROE	11.53%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	105749.17%
GM	N/A
FCFM	2565.35%

ROA(3y)11.46%

ROA(5y)-0.71%

ROE(3y)12.15%

ROE(5y)-0.63%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5Y32.91%

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.02
Debt/FCF	13.58
Debt/EBITDA	N/A
Cap/Depr	15.16%
Cap/Sales	13.86%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	2.43%
Current Ratio	0.52
Quick Ratio	0.52
Altman-Z	4.71

F-Score4

WACC6.99%

ROIC/WACCN/A

Cap/Depr(3y)20.66%

Cap/Depr(5y)19.86%

Cap/Sales(3y)15.7%

Cap/Sales(5y)12.57%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)8.45%

EPS 3YN/A

EPS 5Y23.67%

EPS Q2Q%-194.51%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)17.44%

Revenue growth 3Y-4.71%

Revenue growth 5Y-6.95%

Sales Q2Q%39.52%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-0.1%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y107.57%

FCF growth 3YN/A

FCF growth 5Y-24.11%

OCF growth 1Y107.61%

OCF growth 3YN/A

OCF growth 5Y-24.28%

MPH HEALTH CARE AG KONV (93M1.DE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

5.2 History

5.3 Sustainability

More info and screens